Detalhe da pesquisa
1.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
2.
IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact.
Blood
; 142(2): 131-140, 2023 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36929172
3.
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Blood
; 141(14): 1666-1674, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564045
4.
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.
Br J Haematol
; 204(4): 1159-1175, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390784
5.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541152
6.
Multiple myeloma.
Lancet
; 397(10272): 410-427, 2021 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33516340
7.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438407
8.
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Haematologica
; 107(1): 231-242, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33297668
9.
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Ann Hematol
; 101(10): 2123-2137, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35943588
10.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428632
11.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Br J Haematol
; 193(3): 551-555, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32524584
12.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32656799
13.
Toward personalized treatment in multiple myeloma based on molecular characteristics.
Blood
; 133(7): 660-675, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587529
14.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499244
15.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559051
16.
Neutral tumor evolution in myeloma is associated with poor prognosis.
Blood
; 130(14): 1639-1643, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28827410
17.
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Blood
; 130(1): 30-34, 2017 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28432222
18.
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Haematologica
; 104(7): 1440-1450, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733268
19.
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Blood
; 125(5): 831-40, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428216
20.
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.
Blood
; 123(22): 3414-9, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24733348